Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brooke, M. H.
Right arrow Articles by Miller, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brooke, M. H.
Right arrow Articles by Miller, J. P.
NEUROLOGY 1986;36:146
© 1986 American Academy of Neurology

Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis

Michael H. Brooke, MD, Julaine M. Florence, Scott L. Heller, MD, K. K. Kaiser, Daniel Phillips, MD, Allen Gruber, MD, Debbie Babcock and J. Philip Miller

Departments of Neurology/Neurosurgery (Dr. Brooke, Ms. Florence, Dr. Heller, Mr. Kaiser, Drs. Phillips and Gruber) and Biostatistics (Ms. Babcock and Mr. Miller), Washington University School of Medicine, St. Louis, MO.

A double-blind controlled trial of thyrotropin releasing hormone (TRH) 150 mg IM daily in 30 patients with amyotrophic lateral sclerosis is reported. The drug/placebo was administered for 2 months, followed by a 2-month "wash-out." Evaluation of strength, functional ability, and respiratory functions was performed. A temporary increase in the strength of some muscles was detected following the administration of TRH, but no change in functional performance was noted. Neither the patients nor the investigators believed the effects were of any marked clinical significance. The course of the illness was not altered.

Address correspondence and reprint requests to Dr. Brooke, Washington University School of Medicine, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110.

Supported by a grant from the Muscular Dystrophy Association's Task Force on Therapeutic Trials and by grant RR000-36 to the Clinical Research Center at Washington University School of Medicine.

Accepted for publication November 4, 1985.




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
C.D. Watson, M.J. Hewitt, K.C.F. Fone, S.L. Dickinson, and G.W. Bennett
Behavioural effects of scopolamine and the TRH analogue RX77368 on radial arm maze performance in the rat
J Psychopharmacol, January 1, 1994; 8(2): 88 - 93.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
J. M. Hoffman, J. C. Mazziotta, T. C. Hawk, and R. Sumida
Cerebral Glucose Utilization in Motor Neuron Disease
Arch Neurol, August 1, 1992; 49(8): 849 - 854.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
S. C. Miller and J. E. Warnick
Protirelin (Thyrotropin-Releasing Hormone) in Amyotrophic Lateral Sclerosis: The Role of Androgens
Arch Neurol, March 1, 1989; 46(3): 330 - 335.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
H. Mitsumoto, M. R. Hanson, and D. A. Chad
Amyotrophic Lateral Sclerosis: Recent Advances in Pathogenesis and Therapeutic Trials
Arch Neurol, February 1, 1988; 45(2): 189 - 202.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.